 iHerb | $ 21.42 | |
 Vitacost | $ 22.97 | |
 Daily Vita | $ 20.30 | |
 Walmart | $ 18.00 |
MK-4 supplies a defined vitamin K2 form involved in calcium regulation. The large capsule count makes ongoing use inexpensive.
The amount is modest for the shorter-acting subtype, and no lipid carrier supports absorption. Alfalfa powder is not characterized well enough to provide a meaningful additional role.
The product fits long-term budget users who intentionally choose low-dose MK-4. It remains less practical than MK-7 for sustained daily K2 coverage.
Menaquinone-4 is a usable vitamin K2 form, though it is shorter acting than menaquinone-7, and the menaquinone-4 amount is modest for a short-acting standalone form. The listed vitamin K2 amount is not unnecessarily aggressive, while alfalfa powder adds uncertain value to the focused vitamin K2 formula.
Specific amounts are listed for every supplied active ingredient. No proprietary blend hides active doses, while capsule, softgel, or tablet excipients are not included in the supplied details.
The supplied aggregate satisfaction metric is very strong, and the large amount of aggregate feedback makes the metric highly stable. No review excerpts were provided, so recurring complaints and purpose-specific experiences cannot be checked.
The very low serving cost helps, though the modest menaquinone-4 amount and alfalfa reduce quality. Each serving is inexpensive but provides only modest vitamin K2 depth, while alfalfa powder adds uncertain practical value.
Vitamin K2 supports calcium metabolism, but the MK-4 form is shorter acting than MK-7 at the listed amount. Alfalfa powder adds little clearly defined value to the core vitamin.
The vitamin K subtype and amount are plainly disclosed. MK-4 can interfere with warfarin and other vitamin K antagonist medicines, so users of those drugs need managed, consistent intake.
Vitamin K2 as MK-4 supports calcium placement and may contribute to arterial health. The 100 mcg MK-4 amount is modest because MK-4 is shorter-lived and is often studied at much larger amounts.
The capsule gives clear subtype disclosure but no lipid carrier or branded source. Vitamin K2 can interfere with warfarin and related vitamin K antagonists, so users of those medicines need managed, consistent vitamin K intake.
Vitamin K2 supports calcium handling and may help keep calcium directed toward bone rather than soft tissue. The MK-4 amount is modest relative to doses used in much of the cardiovascular research.
MK-4 is clearly identified, while alfalfa adds little defined cardiovascular activity. Vitamin K2 can oppose warfarin and other vitamin K antagonist anticoagulants, so the intake must remain clinician-guided and consistent.
Vitamin K2 is relevant to bone-protein activation, but the 100 mcg MK-4 amount is modest for this short-lived subtype. The dry capsule also lacks a stated lipid base to support absorption.
Alfalfa powder does not provide a clearly standardized bone-active contribution and distracts from the targeted K2 purpose. MK-4 can interfere with warfarin and related vitamin K antagonists, requiring consistent intake and clinician-guided management for users of those medicines.
| Ingredient | Amount per serving |
|---|---|
Vitamin K2 (Menaquinone-4) | 100 mcg |
Alfalfa powder | 250 mg |
The formula clearly supplies K2 as MK-4, which remains in circulation for less time than MK-7. A very low serving cost is useful, but the modest MK-4 amount and dry capsule format reduce its targeted value. MK-4 can interfere with warfarin and related vitamin K antagonists, so users of those medicines need managed, consistent vitamin K intake.
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
